Investment Rating - The report maintains a "Buy" rating for the company [3] Core Views - The overseas market shows strong growth, while domestic revenue is temporarily under pressure due to delays in hospital procurement. However, with the recovery of bidding activities and the acceleration of medical special bond issuance, domestic growth is expected to resume [1] - The IVD business leads growth, with continuous high-end upgrades in ultrasound structures and an increase in market share across three major segments. The company has also announced a second dividend distribution this year, emphasizing its commitment to shareholder returns [1] Financial Performance Summary - For Q1-Q3 2024, the company achieved revenue of 29.485 billion yuan, a year-on-year increase of 7.99%, and a net profit of 10.637 billion yuan, up 8.16% year-on-year. In Q3 alone, revenue was 8.954 billion yuan, a 1.43% increase year-on-year, while net profit decreased by 9.31% [1] - The overseas revenue for Q1-Q3 grew by 18.3%, with Q3 alone seeing an 18.6% increase, driven by breakthroughs in high-end strategic customers and seed businesses [1] - Domestic revenue for Q1-Q3 grew by 1.9%, but Q3 saw a decline of 9.7% due to industry restructuring and delays in procurement [1] Business Segment Performance - The IVD segment saw a year-on-year growth of 20.9% in Q1-Q3, with its revenue share reaching 39%, surpassing the life information and support segment. The chemical luminescence business grew by over 20% [1] - The medical imaging segment reported an 11.4% growth in ultrasound imaging revenue for Q1-Q3, with both overseas and domestic revenues increasing by over 10% [1] - The life information and support segment experienced an 11.7% decline in Q1-Q3, with overseas markets growing over 10% while domestic markets faced a decline of over 20% due to procurement delays [1] Research and Development - The company places a strong emphasis on R&D innovation, launching several new products across its three major product lines in Q3 2024 [1] Dividend Distribution - The company announced a second interim profit distribution plan for 2024, distributing a cash dividend of 16.50 yuan per 10 shares, totaling 2.001 billion yuan, bringing the cumulative dividend total to 31.723 billion yuan [1] Profit Forecast and Investment Advice - Revenue forecasts for 2024-2026 are 39.429 billion yuan, 47.234 billion yuan, and 56.621 billion yuan, with year-on-year growth rates of 12.9%, 19.8%, and 19.9% respectively. Net profit forecasts are 13.151 billion yuan, 15.881 billion yuan, and 19.232 billion yuan, with corresponding growth rates of 13.5%, 20.8%, and 21.1% [2][1]

Investment Rating - Buy rating maintained for Mindray Medical (300760) [1] Core Views - Domestic growth under pressure, while overseas markets continue high growth [1] - Revenue for the first three quarters of 2024 reached RMB 294.8 billion, up 8.0% YoY, with net profit attributable to shareholders of RMB 106.4 billion, up 8.2% YoY [1] - Q3 2024 revenue was RMB 89.5 billion, up 1.4% YoY, but net profit attributable to shareholders declined by 9.3% YoY to RMB 30.8 billion [1] - Domestic market growth slowed to 1.9% in the first three quarters, with a 9.7% decline in Q3, while international market growth remained strong at 18.3% for the first three quarters and 18.6% in Q3 [1] - Europe saw a 30% YoY growth in Q3, while developing markets, particularly in Asia-Pacific and Latin America, grew by 32% and 25% respectively in Q3 [1] - Life Information & Support product line declined by 11.7% in the first three quarters, while Medical Imaging and IVD product lines grew by 11.4% and 20.9% respectively [1] - IVD product line now accounts for 39% of total revenue, surpassing the Life Information & Support product line [1] - Strong cash flow with operating cash flow reaching RMB 110.7 billion in the first three quarters, up 42.5% YoY [1] - Dividend payout ratio remains high, with RMB 16.5 per 10 shares distributed, totaling RMB 2 billion, representing over 65% of Q3 net profit [1] Financial Projections - Revenue for 2024-2026 is projected to be RMB 379.28 billion, RMB 451.50 billion, and RMB 536.02 billion, with YoY growth of 8.6%, 19.0%, and 18.7% respectively [3] - Net profit attributable to shareholders for 2024-2026 is expected to be RMB 130.30 billion, RMB 155.42 billion, and RMB 186.92 billion, with YoY growth of 12.5%, 19.3%, and 20.3% respectively [3] - EPS for 2024-2026 is projected to be RMB 10.75, RMB 12.82, and RMB 15.42, with corresponding PE ratios of 25x, 21x, and 17x [3] Financial Highlights - Operating cash flow for 2024-2026 is projected to be RMB 151.36 billion, RMB 174.63 billion, and RMB 208.99 billion [7] - Net profit for 2024-2026 is expected to be RMB 130.30 billion, RMB 155.42 billion, and RMB 186.92 billion [7] - ROE for 2024-2026 is projected to be 28.3%, 25.2%, and 23.3% [5] - Gross margin is expected to remain stable at around 65% for 2024-2026 [5] Business Segments - Life Information & Support product line declined by 11.7% in the first three quarters of 2024 [1] - Medical Imaging product line grew by 11.4% in the first three quarters of 2024 [1] - IVD product line grew by 20.9% in the first three quarters of 2024, with chemical发光业务增长超过 20% [1] - Overseas localization of IVD products has been initiated in 8 countries, covering Europe, Latin America, South Asia, Southeast Asia, Middle East & Africa, and CIS regions [1]

Investment Rating - Buy (Maintained) [1] Core Views - The company's performance is under short-term pressure, but a recovery is expected next year [1] - Domestic market faces temporary challenges due to low public hospital bidding and weak non-essential medical demand, while the international market performs well [2] - The core in-vitro diagnostics business shows strong growth, with a 20.9% YoY increase in revenue for the first three quarters [3] - The company's 2024-2026 net profit forecasts have been revised downward, but the "Buy" rating is maintained due to expected recovery in equipment procurement [3] Financial Performance - 2024 Q1-3 revenue: 294.85 billion yuan (+7.99% YoY), net profit: 106.37 billion yuan (+8.16% YoY) [2] - Domestic revenue for Q1-3: 174.7 billion yuan (+1.9% YoY), with a 9.7% decline in Q3 [2] - International revenue for Q1-3: 120.2 billion yuan (+18.3% YoY), with Q3 growth of 18.6% [2] - In-vitro diagnostics revenue: 114 billion yuan (+20.9% YoY), accounting for 38.7% of total revenue [3] - Life information and support business revenue: 108.9 billion yuan (-11.7% YoY), accounting for 36.9% of total revenue [3] - Medical imaging revenue: 59.7 billion yuan (+11.4% YoY), accounting for 20.2% of total revenue [3] Financial Forecasts - 2024E revenue: 377.54 billion yuan (+8.08% YoY), net profit: 129.12 billion yuan (+11.48% YoY) [1] - 2025E revenue: 450.50 billion yuan (+19.33% YoY), net profit: 153.63 billion yuan (+18.98% YoY) [1] - 2026E revenue: 530.10 billion yuan (+17.67% YoY), net profit: 180.68 billion yuan (+17.61% YoY) [1] - 2024E EPS: 10.65 yuan, P/E ratio: 25.03x [1] - 2025E EPS: 12.67 yuan, P/E ratio: 21.04x [1] - 2026E EPS: 14.90 yuan, P/E ratio: 17.89x [1] Market Data - Closing price: 266.60 yuan [5] - 52-week low/high: 221.66/351.60 yuan [5] - P/B ratio: 8.71x [5] - Market cap: 323.24 billion yuan [5] Key Financial Metrics - 2024E ROE: 33.04%, ROIC: 33.08% [10] - 2025E ROE: 28.22%, ROIC: 30.96% [10] - 2026E ROE: 24.92%, ROIC: 26.44% [10] - 2024E gross margin: 65.35%, net margin: 34.20% [9] - 2025E gross margin: 64.85%, net margin: 34.10% [9] - 2026E gross margin: 64.72%, net margin: 34.08% [9] Business Segments - In-vitro diagnostics: Strong growth in chemical发光业务, with revenue exceeding 20% growth [3] - Life information and support: Decline in revenue, but微创外科业务增长超过45% [3] - Medical imaging: Growth in high-end and ultra-high-end ultrasound models, with revenue exceeding 30% growth [3]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for long-term development [3]. Core Views - The company's Q3 2024 performance faced short-term pressure, with revenue of 8.954 billion yuan, a year-on-year increase of 1.43%, and a net profit of 3.076 billion yuan, a year-on-year decrease of 9.31% [1][4]. - The international market is driving growth, with revenue from international operations increasing by over 18% year-on-year in the first three quarters of 2024, particularly strong in Europe and the Asia-Pacific region, where growth exceeded 30% [1][2]. - The company has maintained high R&D investment, with 2.84 billion yuan spent in the first three quarters of 2024, accounting for 9.64% of revenue, and has launched multiple new products across its three main business areas [2]. Summary by Sections Financial Performance - For Q3 2024, the company reported revenue of 8.954 billion yuan, net profit of 3.076 billion yuan, and a non-recurring net profit of 3.057 billion yuan, with respective year-on-year changes of +1.43%, -9.31%, and -8.62% [1][4]. - The gross profit margin for Q3 was 61.69%, down 5.52 percentage points year-on-year, while the net profit margin was 34.92%, down 3.51 percentage points year-on-year [1]. R&D and Product Development - The company invested 2.84 billion yuan in R&D in the first three quarters of 2024, with a focus on expanding its product lines in in vitro diagnostics, medical imaging, and life information and support [2]. - As of September 30, 2024, the company had applied for 11,358 patents, with 5,563 granted, including 2,747 invention patents [2]. Market Outlook - The international in vitro diagnostics segment saw revenue growth exceeding 30% in the first three quarters of 2024, while the life information and support segment grew over 10% [2]. - The company has enhanced its brand's international influence by showcasing innovative products at international events, which supports future growth opportunities [2].

海外业务快速增长，持续关注设备更新执 行进展 ——迈瑞医疗 2024 年三季报点评 核心观点 ⚫ 业绩稳健增长，经营性现金流显著提升。公司发布 2024 年三季报，2024 年前三季 度，公司实现营收 294.8 亿元（同比+8.0%）；归母净利润 106.4 亿元（同比 +8.2%），剔除汇兑损益影响后的增速为 11%。2024 年第三季度，公司实现营收 89.5亿元（同比+1.4%）；归母净利润30.8亿元（同比-9.3%）。从盈利能力来看， 第三季度公司归母净利率 34.4%，高于 2023 全年净利率水平。此外，前三季度公司 实现经营性现金流净额 110.7 亿元（同比+42.5%），将向全体股东派发二次中期现 金分红约 20 亿元，分红比例超过 65%。 ⚫ 体外诊断迅速发展，生命信息与支持业务短暂承压。分产线来看，体外诊断产线前 三季度实现收入 114.0 亿元（同比+20.9%），主要系加速推动海外本地化生产和中 大样本量实验室突破所致，其中国际业务增长超 30%。医学影像产线前三季度实现 收入 59.7 亿元（同比+11.4%），主要受益于去年底上市的全身应用超高端超声 Resona A20 ...

医药生物 | 证券研究报告 — 业绩评论 2024 年 10 月 31 日 300760.SZ 买入 原评级：买入 市场价格:人民币 271.24 板块评级:强于大市 股价表现 (%) 今年 至今 1 个月 3 个月 12 个月 绝对 (7.6) 2.3 5.5 2.0 (20%) (12%) (4%) 3% 11% 19% Oct-23Dec-23Jan-24Feb-24Mar-24Apr-24May-24Jun-24Jul-24Aug-24Sep-24Oct-24 迈瑞医疗 深圳成指 相对深圳成指 (19.7) (8.5) (18.4) (5.9) | --- | --- | --- | |-------------------------------|------------|------------| | | | | | 发行股数 ( 百万 ) | | 1,212.44 | | 流通股 ( 百万 ) | | 1,212.44 | | 总市值 ( 人民币 百万 ) | | 328,862.60 | | 3 个月日均交易额 ( 人民币 | 百万 ) | 1,926.93 | | 主要股东 | | | | ...

迈瑞医疗（300760.SZ）2024 年三季报点评 业绩短期承压，看好后续复苏态势 2024 年 10 月 31 日 [盈利预测与财务指标 Table_Forcast] ➢ 事件：2024 年 10 月 29 日，迈瑞医疗发布 2024 年三季报业绩。前三季度 公司实现营业收入 294.85 亿元，同比上升 7.99%，归母净利润 106.37 亿元， 同比上升 8.16%；扣非净利润 104.37 亿元，同比上升 7.75%。单季度看，公司 Q3 实现收入 89.54 亿元，同比上升 1.43%；归母净利润 30.76 亿元，同比下降 9.31%；扣非净利润 30.57 亿元，同比下降 8.62%。 ➢ 分区域来看，国际市场持续发力，国内短期需求端较为疲软。受益于海外高 端战略客户和中大样本量实验室的持续突破，以及动物医疗、微创外科、AED 等 种子业务的放量，国际市场前三季度增长超过 18%，其中欧洲和亚太市场增长均 超过了 30%。国内因医疗领域整顿和医疗设备更新项目等多因素影响导致医院 采购推迟，同时医院建设资金紧张和非刚性医疗需求低迷，国内市场前三季度增 长不到 2%。 ➢ 分产线来看，24Q3 ...

Investment Rating - Maintains a "Buy" rating with a target price of RMB 350 [1][3] Core Views - Domestic revenue is expected to remain under pressure in 4Q24, with a potential recovery in 2025 [1] - Overseas business continues to grow steadily, while domestic growth is sluggish due to anti-corruption measures and delayed equipment renewal tenders [1] - 3Q24 revenue growth was modest, with domestic revenue declining by 10% YoY, while overseas revenue grew by 19% YoY [1] - Life Information & Support segment revenue fell by over 20% YoY in 3Q24, while IVD and Medical Imaging grew by less than 10% and 3% respectively [1] - Gross margin in 3Q24 declined by 5.5 ppts YoY, mainly due to accounting adjustments, but remained stable on a like-for-like basis [1] - Medical special bonds and local special bonds issuance accelerated in September 2024, but the impact on 4Q24 performance is expected to be limited [1] - The company plans to reduce inventory levels from 4 months to 2 months by the end of 2024, which may pressure 4Q24 revenue growth [1] - Full-year 2024 revenue growth is expected to slow to 7% YoY, with a significant recovery anticipated in 2025 as equipment renewal projects materialize [1] Financial Performance and Forecasts - 2024E revenue is projected at RMB 37.4 billion, with a 7.1% YoY growth, while 2025E revenue is expected to grow by 21% YoY to RMB 45.3 billion [2] - 2024E net profit attributable to shareholders is forecasted at RMB 12.5 billion, with a 7.6% YoY increase, and 2025E net profit is expected to grow by 21% YoY to RMB 15.1 billion [2] - Gross margin for 2024E is projected at 64.2%, slightly lower than 2023A's 66.2% [4] - Operating cash flow for 2024E is expected to be RMB 15.6 billion, with capital expenditures of RMB 6.8 billion [5] Dividend Policy - The company announced a second dividend of RMB 1.65 per share for 2024, maintaining a payout ratio of 65% [1] - The single dividend yield is 0.6% based on the closing price on the announcement date [1] Valuation Metrics - The target price of RMB 350 implies a 28x 2025E PE, in line with the 3-year historical average [1] - 2024E PE is projected at 26.4x, declining to 21.8x in 2025E [2] - The dividend yield for 2024E is expected to be 2.5%, increasing to 3.0% in 2025E [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights that external policy impacts have affected short-term performance, but there is optimism regarding domestic equipment upgrades and continuous breakthroughs in overseas markets [1] - The company has shown resilience in its domestic business despite policy disruptions, with strong performance in overseas markets, particularly in high-end strategic clients and large sample laboratories [1][2] - The report anticipates rapid growth in the domestic market driven by new medical infrastructure and recovery in hospital diagnostics, while overseas high-end clients are expected to continue to expand [1][6] Financial Performance Summary - **Revenue Forecasts**: - 2022A: 30,366 million - 2023A: 34,932 million - 2024E: 38,391 million - 2025E: 44,759 million - 2026E: 52,249 million - Year-on-Year Growth Rates: 20% (2022), 15% (2023), 10% (2024), 17% (2025), 17% (2026) [1] - **Net Profit Forecasts**: - 2022A: 9,607 million - 2023A: 11,582 million - 2024E: 13,375 million - 2025E: 15,677 million - 2026E: 18,301 million - Year-on-Year Growth Rates: 20% (2022), 21% (2023), 15% (2024), 17% (2025), 17% (2026) [1] - **Earnings Per Share (EPS)**: - 2022A: 7.92 - 2023A: 9.55 - 2024E: 11.03 - 2025E: 12.93 - 2026E: 15.09 [1] - **Profitability Ratios**: - Return on Equity (ROE): 30% (2022), 35% (2023), 29% (2024), 25% (2025), 23% (2026) [1] - Price-to-Earnings (P/E) Ratio: 34.2 (2022), 28.4 (2023), 24.6 (2024), 21.0 (2025), 18.0 (2026) [1] Market and Business Insights - The company has experienced a slight slowdown in growth due to domestic medical regulations, but its overseas business remains robust, with significant revenue contributions from high-end products and new business lines such as minimally invasive surgery and animal healthcare [1][2] - The report notes that the company's market share in the domestic market is expected to increase, with the in vitro diagnostics segment becoming the largest revenue contributor [1][2] - The company is well-positioned to benefit from the acceleration of special bond issuance and the gradual recovery of its monitoring business [1][6]

外部政策影响短期业绩,看好国内设备更新落地+海外市场持续突 40.0 迈瑞医疗 (300760.SZ) 医疗器械 证券研究报告/公司点评报告 2024 年 10 月 30 日 | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------------------------------------------------------------------------------------------------- ...